Literature DB >> 2180659

Feasibility of adjustment of insulin dose by insulin-requiring type II diabetic patients.

J C Floyd1, M M Funnell, I Kazi, C Templeton.   

Abstract

Type II (non-insulin-dependent) diabetes accounts for most of the diabetes morbidity and expense, yet no systematic study of the effects of intensification of treatment by such patients who require insulin treatment has been conducted. Therefore, patients were recruited from our diabetes clinics, and by random assignment, experimental and control groups were created (n = 26 and 27, respectively) that were not different at 0 mo regarding 20 demographic, physiological, and treatment variables. Experimental patients practiced an algorithm for adjustment of insulin dosage based on daily prebreakfast capillary blood glucose (CBG) measurements and any symptomatic hypoglycemia. At 2-, 4-, and 6-mo visits, records of CBG measurements were available to the physicians (n = 7), who changed insulin dosages of both groups ad libitum. Feasibility of the experimental treatment is evidenced by study completion by 87% of enrollers, monitoring on 88% of days, accuracy of CBG recording (recorded as percentage of memory meter value, 100.8), weight gain not exceeding that of control subjects, practice of treatment algorithm to effect changes in insulin dosage, modest increase in frequency of mild insulin reactions, and a decrease of glycosylated hemoglobin into the normal range.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2180659     DOI: 10.2337/diacare.13.4.386

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  2 in total

Review 1.  Clinical practice guidelines for treatment of diabetes mellitus. Expert Committee of the Canadian Diabetes Advisory Board.

Authors: 
Journal:  CMAJ       Date:  1992-09-01       Impact factor: 8.262

2.  An educational program for insulin self-adjustment associated with structured self-monitoring of blood glucose significantly improves glycemic control in patients with type 2 diabetes mellitus after 12 weeks: a randomized, controlled pilot study.

Authors:  Daniel Dutra Romualdo Silva; Adriana Aparecida Bosco
Journal:  Diabetol Metab Syndr       Date:  2015-01-15       Impact factor: 3.320

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.